BRAF and colorectal carcinoma: However, we can suggest a clue that the de novo difference in the immune profile of BRAF-MT CRC might be associated with treatment responses considering that the tumor tissue used for the multiplex IHC to evaluate the tumor immune profile was obtained before treatment.